Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera”), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Our lead product is ILUVIEN, now approved for marketing in the U.S. and 15 European countries for the treatment of diabetic macular edema.
Location: United States, Georgia, Alpharetta
Member count: 201-500
Phone: +1 678-990-5740
Founded date: 2003
Investors 4
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| 07.08.2021 | New Enterp... | nea.com |
| - | Hercules C... | htgc.com |
| - | Sofinnova ... | sofinnova.... |
Mentions in press and media 10
| Date | Title | Description | Category | Author | Source |
| 02.06.2022 | Alimera Sc... | ATLANTA, June 02, 2022 (GLOBE ... | - | - | globenewsw... |
| 14.04.2021 | ALIMERA SC... | Alimera grants exclusive licen... | - | - | marketscre... |
| 14.04.2021 | Alimera Sc... | Alimera Sciences, Inc. (Nasdaq... | - | - | marketscre... |
| 18.02.2014 | Alimera ra... | Alimera Sciences (NSDQ:ALIM) r... | - | Arezu Sarv... | massdevice... |
| 03.10.2012 | Biotech co... | Solution/Product: The company ... | - | - | medcitynew... |
| 23.04.2010 | Morning Re... | Why people hate insurance comp... | - | - | medcitynew... |
| 18.03.2008 | Life-scien... | TODAY’S HEADLINES: Luminous Me... | - | - | venturebea... |
| 17.01.2008 | Life scien... | TODAY’S HEADLINES: TransEnter... | - | - | venturebea... |
| - | Biotech co... | Alimera Sciences, a public com... | - | - | medcitynew... |
| - | Morning Re... | Highlights of the important an... | - | - | medcitynew... |